Joshua June, DO
Rheumatology · Lansing, MINPI 1205147873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,309 of the $109,672 with a category attached, or 60.5%. 40 manufacturers reported payments, led by Johnson & Johnson at 36.1% of the total. Reporting peaked in 2019 at $29,748 and has fallen 58.2% since, to $12,424 in 2025. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,627 payments — averaging $67.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$40K
- Mallinckrodt Enterprises LLC$23K
- Mallinckrodt Hospital Products Inc.$11K
- Janssen Scientific Affairs, LLC$10K
- Amgen$7K
- AbbVie$4K
- plus $14K from 34 others
Across 386 payments — averaging $6210.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$614K
- AbbVie$573K
- GSK$351K
- Genentech, Inc.$145K
- UCB SA$134K
- Mallinckrodt Enterprises LLC$105K
- plus $476K from 17 others
What the payments were for
- Consulting fees$12,78512%
- Speaking & faculty fees$66,30960%
- Travel & lodging$2,2102%
- Food & beverage$27,48625%
- Education$8821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,672 in reported general payments places this provider in the 90th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 49 | $557,080 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $485,436 |
| Humira PenAdalimumab | 34 | $284,188 |
| Enbrel SureclickEtanercept | 29 | $212,276 |
| RinvoqUpadacitinib | 28 | $173,344 |
| Orencia ClickjectAbatacept | 24 | $134,121 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $117,620 |
| HumiraAdalimumab | 16 | $113,162 |
| EnbrelEtanercept | 13 | $98,523 |
| Actemra ActpenTocilizumab | 15 | $72,134 |
| BenlystaBelimumab | 13 | $62,371 |
| Hydroxychloroquine Sulfate | 745 | $46,626 |
| Mycophenolate Mofetil | 132 | $13,914 |
| MethotrexateMethotrexate Sodium | 381 | $13,451 |
| Leflunomide | 204 | $13,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $4,127 | $286,50644 claims |
| AmgenEnbrel | $7,398 | $98,52313 claims |
| GSKBenlysta | $175 | $62,37113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Lansing
- Mhd Iyad Al ShwafLansing$24K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.